ArticleBMC cancer2026
Association between four indirect indicators of insulin resistance and lung cancer: evidence from UK biobank and Mendelian randomization analysis.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundInsulin resistance (IR) has been increasingly linked to cancer development and progression, but its association with lung cancer (LC) remains unclear. This prospective study investigated the association between four indirect IR indicators—triglyceride-glucose (TyG) index, TyG combined with body mass index (TyG-BMI), triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C), and metabolic score for IR (METS-IR), and LC risk.
methodsA total of 388,013 participants without previous cancer at baseline from the UK Biobank were included. Cox hazards regression models were used to examine the associations between four indirect indicators of IR and LC. Restricted cubic splines (RCS) evaluated nonlinear associations. The discriminatory ability of each index was assessed using the area under the receiver operating characteristic (ROC) curve. Sensitivity analyses were performed to test robustness. In addition, Mendelian randomization (MR) analysis was performed to explore potential causal relationships.
resultsAmong 388,013 cancer-free participants from UK Biobank, 3527 incident LC cases were documented during a median follow-up of 13.25 years. Kaplan-Meier analysis revealed associations between higher levels of four indicators and increased cumulative LC incidence. In fully adjusted Cox regression models, METS-IR exhibited the strongest association with overall LC, with the highest quartile associated with an increased risk (hazard ratio: 1.24, 95% confidence interval: 1.05–1.47). No statistically significant associations were observed for lung adenocarcinoma or lung squamous cell carcinoma. In contrast, several indicators remained associated with small cell lung cancer (SCLC), with elevated risks observed for TG/HDL-C (1.52, 1.03–2.25), METS-IR (2.30, 1.29–4.11), and TyG-BMI (2.22, 1.20–4.08) in the highest quartiles. RCS analyses suggested predominantly linear associations. ROC curve analyses indicated modest discriminatory performance, with relatively higher discrimination for SCLC, particularly for the TG/HDL-C ratio and TyG index. However, MR analyses did not provide evidence supporting a causal association.
conclusionsThis prospective cohort study suggested that indirect indicators of insulin resistance are associated with the risk of overall lung cancer, particularly small cell lung cancer, whereas no significant associations were observed for lung adenocarcinoma or lung squamous cell carcinoma. However, MR analyses did not support a causal relationship. These findings suggest that these indicators may reflect underlying metabolic vulnerability rather than direct causal mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.